Robert John Young
13Patents
2h-index
19Co-inventors
43Inventor score
Filing activity: Nov 29, 2000 → Oct 11, 2006
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6355689B1 | Nitric oxide synthase inhibitors | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7084139B2 | Pyrrolidin-2-one derivatives as inhibitors of factor Xa | Human Necessities | 2 | Expired |
| US7226929B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | Human Necessities | 2 | Expired |
| US7282497B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | Human Necessities | 1 | Expired |
| US6495606B1 | Nitric oxide synthase inhibitors | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7179835B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US7186717B2 | Pyrrolidine derivatives as Factor Xa inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US7482374B2 | Pyrrolidine-2-ones as Factor Xa inhibitors | Human Necessities | 0 | Expired |
| US7235544B2 | 3-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor Xa | Chemistry; Metallurgy | 0 | Expired |
| US7517879B2 | Pyrrolidine derivatives as factor Xa inhibitors | Chemistry; Metallurgy | 0 | Active |
| US7326785B2 | Pyrrolidine derivatives as factor XA inhibitors | Chemistry; Metallurgy | 0 | Active |
| US7645338B2 | Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide | Human Necessities | 0 | Expired |
| US7429587B2 | Pyrrolidine derivatives as factor Xa inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.